Dana-Farber/Boston Children's Cancer and Blood Disorders Center | Education
Undergraduate School
College of the Holy Cross
Worcester, MA
Medical School
University of Massachusetts at Worcester
Worcester, MA
Internship
Pediatrics
Massachusetts General Hospital
Boston, MA
Residency
Pediatrics
Massachusetts General Hospital
Boston, MA
Fellowship
Pediatric Oncology
Dana-Farber Cancer Institute/Boston Children's Hospital
Boston, MA
Dana-Farber/Boston Children's Cancer and Blood Disorders Center | Publications
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen. Blood Cancer J. 2024 10 31; 14(1):191. View Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen. Abstract
Outpatient Management of Fever and Neutropenia in Low-risk Children with Solid Tumors: A Quality Improvement Initiative. Pediatr Qual Saf. 2024 Sep-Oct; 9(5):e771. View Outpatient Management of Fever and Neutropenia in Low-risk Children with Solid Tumors: A Quality Improvement Initiative. Abstract
Nucleotide depletion promotes cell fate transitions by inducing DNA replication stress. Dev Cell. 2024 08 19; 59(16):2203-2221.e15. View Nucleotide depletion promotes cell fate transitions by inducing DNA replication stress. Abstract
IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia. Biomedicines. 2024 Jan 01; 12(1). View IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia. Abstract
Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Clin Cancer Res. 2023 11 14; 29(22):4613-4626. View Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Abstract
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. Blood Adv. 2023 04 11; 7(7):1092-1102. View Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. Abstract
Hemophagocytic lymphohistiocytosis as an etiology of bone marrow failure. Front Oncol. 2022; 12:1016318. View Hemophagocytic lymphohistiocytosis as an etiology of bone marrow failure. Abstract
Simulated Umbilical Venous Catheter Placement Improves Resident Competence and Confidence. Cureus. 2020 Oct 05; 12(10):e10810. View Simulated Umbilical Venous Catheter Placement Improves Resident Competence and Confidence. Abstract
Peripheral blood smears of children with multisystem inflammatory syndrome demonstrate prominence of early myeloid forms with morphologic evidence of toxic change. Pediatr Blood Cancer. 2021 01; 68(1):e28551. View Peripheral blood smears of children with multisystem inflammatory syndrome demonstrate prominence of early myeloid forms with morphologic evidence of toxic change. Abstract
Outcomes of a clinical pathway for primary outpatient management of pediatric patients with low-risk febrile neutropenia. Pediatr Blood Cancer. 2019 07; 66(7):e27679. View Outcomes of a clinical pathway for primary outpatient management of pediatric patients with low-risk febrile neutropenia. Abstract
The Massachusetts General Hospital Guide to Medical Care in Patients with Autism Spectrum Disorder. 2018.
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015 Jan; 64(1):77-83. View Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Abstract
Usefulness of pancreatitis-associated protein, a novel biomarker, to predict severity of disease in ambulatory patients with heart failure. Am J Cardiol. 2014 Jan 01; 113(1):123-6. View Usefulness of pancreatitis-associated protein, a novel biomarker, to predict severity of disease in ambulatory patients with heart failure. Abstract
J Crohns Colitis. A phase 1, double-blind placebo-controlled single-dose study to determine the immune response to systemic and mucosal antigenic challenge in the presence of vedolizumab. 2013; 7(1):S248.
Inflammatory Bowel Diseases. No association between vedolizumab exposure and serum JC virus levels. 2011; 17(Suppl 1):S56.